粪便具核梭杆菌与clbA+大肠埃希菌DNA检测在结直肠癌诊断中的价值

doi:10.3969/j.issn.1673-8640.2020.04.006

摘要/Abstract

摘要：

目的探讨粪便具核梭杆菌与clbA+大肠埃希菌检测诊断结直肠癌的价值。方法采用实时荧光定量聚合酶链反应（PCR）检测58位健康对照者、38例腺瘤患者及115例肠癌患者粪便样本中具核梭杆菌与clbA+大肠埃希菌DNA相对表达量。结果 clbA+大肠埃希菌DNA相对表达量健康对照组为0.001 6（0.000 46~0.004 9）、腺瘤组为0.002 6（0.000 45~0.008 8）、肠癌组为0.006 3（0.002 0~0.036）,具核梭杆菌DNA相对表达量健康对照组为0.001 0（0.000 31~0.002 9）、腺瘤组为0.003 3（0.001 1~0.011 0）、肠癌组为0.006 4（0.002 9~0.012 0）。健康对照组、肠癌组clbA+大肠埃希菌及具核梭杆菌DNA相对表达量差异有统计学意义（P<0.000 1）。受试者工作特征（ROC）曲线分析结果显示clbA+大肠埃希菌及具核梭杆菌诊断肠癌的曲线下面积（AUC）分别为0.712、0.750,最佳临界值分别为0.003 3、0.002 3,敏感性分别为64.32%、80.87%,特异性分别为65.52%、68.97%。clbA+大肠埃希菌及具核梭杆菌阳性检出率在早期和晚期肠癌中差异无统计学意义（P>0.05）,二者对早期肠癌的检出率分别为75.7%、80.5%,较癌胚抗原（CEA）及粪便隐血试验（FOBT）敏感性高。结论具核梭杆菌与clbA+大肠埃希菌在结直肠癌患者粪便中显著富集,可作为结直肠癌潜在的早筛生物标志物。

关键词: 具核梭杆菌, clbA+大肠埃希菌, 生物标志物, 粪便, 结直肠癌

Abstract:

Objective To investigate the role of fecal DNA level of Fusobacterium nucleatum and clbA+ Escherichia coli in the diagnosis of colorectal cancer. Methodse Real-time fluorescence quantitation polymerase chain reaction（PCR） was used to determine the DNA level of Fusobacterium nucleatum and clbA+Escherichia coli in 58 healthy subjects,38 adenoma patients and 115 colorectal cancer patients. Results The DNA levels of clbA+ Escherichia coli were 0.001 6（0.000 46-0.004 9） in healthy control group,0.002 6（0.000 45-0.008 8） in adenoma group and 0.006 3（0.002 0-0.036） in colorectal cancer group. Those of Fusobacterium nucleatum were 0.001 0（0.000 31-0.002 9）in healthy control group,0.003 3（0.001 1-0.011 0） in adenoma group and 0.006 4（0.002 9-0.012 0） in colorectal cancer group. The DNA level of Fusobacterium nucleatum and clbA+Escherichia coli in colorectal cancer group had statistical significance compared with healthy control group（P<0.000 1）. Receiver operating characteristic（ROC） curve analysis showed that the areas under curves（AUC）of clbA+ Escherichia coli and Fusobacterium nucleatum in the diagnosis of colorectal cancer were 0.712 and 0.750,respectively. The optimal cut-off values were 0.003 3 and 0.002 3,the sensitivities were 64.32% and 80.87%,and the specificities were 65.52% and 68.97%,respectively. The positive rates of clbA+ Escherichia coli and Fusobacterium nucleatum in the early stage of colorectal cancer were 75.7% and 80.5%,which were higher than those of carcinoembryonic antigen（CEA） and fecal occult blood test（FOBT）,and there was no statistical significance between early and advanced stages（P>0.05）. Conclusions The clbA+ Escherichia coli and Fusobacterium nucleatum are abundant in feces from colorectal cancer patients,which may be used as potential early determination biomarkers in colorectal cancer.

Key words: Fusobacterium nucleatum, clbA+Escherichia coli, Biomarker, Feces, Colorectal cancer

中图分类号:

R379.9

刘艳, 龙吟, 潘伟杰, 张通, 翁文浩, 俞莹. 粪便具核梭杆菌与clbA+大肠埃希菌DNA检测在结直肠癌诊断中的价值[J]. 检验医学, 2020, 35(4): 314-317.

LIU Yan, LONG Yin, PAN Weijie, ZHANG Tong, WENG Wenhao, YU Ying. Role of fecal DNA level of Fusobacterium nucleatum and clbA+ Escherichia coli in the diagnosis of colorectal cancer[J]. Laboratory Medicine, 2020, 35(4): 314-317.

图/表 3

参考文献 14.

1.	CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
2.	NOUGAYRÈDE J P,HOMBURG S,TAIEB F,et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells[J]. Science,2006,313(5788):848-851.
3.	ZHANG S,CAI S,MA Y.Association between Fusobacterium nucleatum and colorectal cancer:progress and future directions[J]. J Cancer,2018,9(9):1652-1659.
4.	YANG Y,WENG W,PENG J,et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear factor-κB,and up-regulating expression of microRNA-21[J]. Gastroenterology,2017,152(4):851-866.e24.
5.	YU T,GUO F,YU Y,et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell,2017,170(3):548-563.e16.
6.	LADABAUM U,DOMINITZ J A,KAHI C,et al.Strategies for colorectal cancer screening[J]. Gastroenterology,2020,158(2):418-432.
7.	SONG L L,LI Y M.Current noninvasive tests for colorectal cancer screening: an overview of colorectal cancer screening tests[J]. World J Gastrointest Oncol,2016,8(11):793-800.
8.	LI J N,YUAN S Y.Fecal occult blood test in colorectal cancer screening[J]. J Dig Dis,2019,20(2):62-64.
9.	SUBRAMANIAN S,TANGKA F K SL,HOOVER SS,et al. Costs of colorectal cancer screening provision in CDC's Colorectal Cancer Control Program:comparisons of colonoscopy and FOBT/FIT based screening[J]. Eval Program Plann,2017,62:73-80.
10.	SARASTE D,MARTLING A,NILSSON P J,et al.Complications after colonoscopy and surgery in a population-based colorectal cancer screening programme[J]. J Med Screen,2016,23(3):135-140.
11.	TJALSMA H,BOLEIJ A,MARCHESI J R,et al.A bacterial driver-passenger model for colorectal cancer:beyond the usual suspects[J]. Nat Rev Microbiol,2012,10(8):575-582.
12.	CUEVAS-RAMOS G,PETIT C R,MARCQ I,et al.Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells[J]. Proc Natl Acad Sci U S A,2010,107(25):11537-11542.
13.	ABED J,EMGÅRD J E,ZAMIR G,et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc[J]. Cell Host Microbe,2016,20(2):215-225.
14.	WACHSMANNOVA L,MEGO M,STEVURKOVA V,et al.Novel strategies for comprehensive mutation screening of the APC gene[J]. Neoplasma,2017,64(3):338-343.

组别	例数	clbA+大肠埃希菌DNA	具核梭杆菌DNA	clbA+大肠埃希菌DNA与具核梭杆菌DNA联合	CEA	FOBT
早期肠癌组	87	54（75.7）	70（80.5）	71（81.6）	22（25.3）	44（50.6）
晚期肠癌组	28	20（71.4）	23（82.1）	22（78.6）	15（53.6）	14（50.1）
χ²值		0.452 0	0.006 0	0.006 0	6.523 0	0.027 0
P值		0.501 2	0.936 8	0.936 8	0.010 6	0.869 4

组别	例数	clbA+大肠埃希菌DNA	具核梭杆菌DNA	clbA+大肠埃希菌DNA与具核梭杆菌DNA联合	CEA	FOBT
早期肠癌组	87	54（75.7）	70（80.5）	71（81.6）	22（25.3）	44（50.6）
晚期肠癌组	28	20（71.4）	23（82.1）	22（78.6）	15（53.6）	14（50.1）
χ²值		0.452 0	0.006 0	0.006 0	6.523 0	0.027 0
P值		0.501 2	0.936 8	0.936 8	0.010 6	0.869 4

[1]	李梁珊, 赵虎, 王诗雯. 基于加权基因共表达网络分析筛选结直肠癌潜在的预后生物标志物[J]. 检验医学, 2023, 38(9): 825-832.
[2]	孙泽朋, 王洪彬, 王建东, 宋德伟, 肖鹏. 心肌损伤多肽和蛋白类标志物方法学分析和进展[J]. 检验医学, 2023, 38(8): 784-789.
[3]	朱日祥, 殷杰. 可溶性生长刺激表达基因2蛋白与结直肠癌患者临床病理特征和预后的关系[J]. 检验医学, 2023, 38(7): 629-633.
[4]	张敏, 王彬宇, 迟伟群, 刘禹. 外泌体非编码RNA作为疾病诊断生物标志物的研究进展[J]. 检验医学, 2023, 38(6): 594-598.
[5]	江梦颖, 刘鷖雯, 何怡青, 许静, 杨翠霞, 高锋, 杜艳. 血清S1P检测在结直肠癌早期诊断中的临床价值[J]. 检验医学, 2023, 38(4): 307-312.
[6]	张国良, 刘鷖雯, 何怡青, 许静, 杨翠霞, 高锋, 刘华. 血清HYAL1、HA在结直肠癌辅助诊断和疗效监测中的价值[J]. 检验医学, 2023, 38(4): 313-319.
[7]	杨婕琳, 王晓媛, 李海霞. TRX和TXNIP在结直肠癌组织中的表达及其交互作用[J]. 检验医学, 2023, 38(4): 330-336.
[8]	刘庆阳, 袁建明, 夏进军, 姜风英, 王秋波, 王晓明. 基于GEO数据库和临床样本验证CXCL9作为类风湿关节炎生物标志物的研究[J]. 检验医学, 2023, 38(12): 1121-1129.
[9]	周福荣, 李龑杼, 刘勇敢. lncRNA SNP在结直肠癌易感性预测和预后评估中的应用[J]. 检验医学, 2023, 38(12): 1206-1210.
[10]	鲁启源, 卢建华. 人工关节假体周围感染诊断生物标志物研究进展[J]. 检验医学, 2023, 38(10): 997-1002.
[11]	陈雪薇, 李一荣. 基于GEO数据库筛选代谢综合征潜在生物标志物[J]. 检验医学, 2023, 38(1): 32-38.
[12]	吴亚婷, 李卓林, 雷艳, 贾如雪, 张胜行, 王水良. 尿液中miRNA作为常见恶性肿瘤生物标志物研究进展[J]. 检验医学, 2023, 38(1): 94-99.
[13]	王芮, 李朝燕, 赵爱光. 循环肿瘤DNA检测在胃癌诊疗中的应用现状[J]. 检验医学, 2022, 37(9): 877-881.
[14]	邬燕倩, 俞翀, 沈鹭, 郑浩然, 洪叶挺. 体液piRNA作为疾病潜在生物标志物的研究进展[J]. 检验医学, 2022, 37(8): 782-786.
[15]	朱赟洁, 马峥尧, 沈敏娜, 周琰, 黄斐, 陈馨宁, 张春燕, 王蓓丽, 郭玮. 结直肠癌患者血浆cfDNA检测方法的建立及临床应用评估[J]. 检验医学, 2022, 37(6): 561-567.